Phillip Palmbos MD,PhD
Fellow, Division Hematology/Oncology
C369 Med Inn; 5848
(734) 936-0832 ppalmbos@umich.edu
1996-2000 Calvin College B.S. with Honors in Biology and minor in Biochemistry
2000-2008 University of Michigan Medical School, Medical Scientist Training Program
2000-2002 Medical School Years 1 and 2
2002-2006 PHD in Cellular and Molecular Biology
2006-2008 Medical School Years 3-4
2008-2010 Internal Medicine Residency, University of Michigan
2010- Current Fellowship Hematology/Oncology Fellowship
2002 USMLE STEP 1 Certification
2008 USMLE STEP 2 Certification
2010 USMLE STEP 3 Certification
2011 American Board of Internal Medicine, Board Certified in Internal Medicine
1.
Bladder cancer- molecular mechanisms, transgenic models and biomarkers.
2.
DNA damage response pathways- PhD work addressed the molecular pathways governing the nonhomologous endjoing pathway of DNA double-strand break repair.
:
2010- current Hematology/Oncology Fellowship, University of Michigan
2008-2010 Internal Medicine Residency, University of Michigan
2008- current Physician-Scientist Training Program (ABIM Research Pathway),
University of Michigan.
2003- Teacher Assistant for first-year medical school Normal Cell course, University of
Michigan
2000- 2008 Fellow in Medical Scientist Training Program, University of Michigan
1998-2000 Teacher Assistant, Department of Biology, Calvin College, MI
1997-2000 Research Assistant, Department of Biology, Calvin College, MI
2012 NIH Loan Repayment Grant Awardee
2012 American Society Clinical Oncology, Conquering Cancer Merit Award,
Genitourinary Cancers Symposium, San Francisco, California
2011 University of Michigan Cancer Center Fall Symposium First Place Abstract Award
2004-2005 Loeb Predoctoral Fellowship, Cancer Biology Training Grant Recipient,
University of Michigan

2004 Travel Grant recipient, American Society for Microbiology DNA Repair
Symposium, Southhampton, Bermuda
2000 Honors Graduate, Calvin College, MI
1999-2000 Dirkse Memorial Medical Scholarship, Calvin College, MI
2012- present Member American Association of Cancer Research
2010- American Society for Clinical Oncology
2000-2008 American Medical Association- student member
2005 Planning Committee- CMB Genome Instability Short-course, University of
Michigan
2004-2006 Programs Activities Committee MSTP Program, University of Michigan
2000-2002 Vice president Christian Medical Association, University of Michigan
2001 and 2002 Medical relief teams in Olancho, Honduras
1.
ATDC drives bladder cancer formation by promoting methylation of the PTEN promoter and inhibition of p53 function. Poster Presentation at American Society for Cancer Research Meeting 4/2013.
2.
ATDC is Novel Oncogene in Bladder Cancer. Poster Presentation at American
Society of Clinical Oncology Meeting. Chicago, IL. 6/2012
3.
ATDC is a Novel Oncogene in Bladder Cancer. (Merit Award) Poster
Presentation at American Society of Clinical Oncology Genitourinary
Symposium. San Francisco, CA. 2/2012.
4.
ATDC, an Oncogene in Bladder Cancer. Oral Presentation at the University of
Michigan Cancer Center Fall Research Symposium. First Place Abstract.
11/2011.
1.
Palmbos PL, Hussain, MH. Non-castrate metastatic prostate cancer: Have the treatment options changed? Seminars in Oncology. In Press . 2013
2.
Wang L, Yang H, Palmbos PL , Ney G, Detzler TA, Coleman D, Leflein J, Davis
M, Zhang M, Tang W, Hicks K, Helchowski CM, Prasad J, Lawrence T, Xu L,
Yu X, Canman CE, Ljungman M, Simeone DM.
Phosphorylation of ATDC via
ATM/ MAPKAP Kinase 2 Signaling Mediates Radioresistance of Pancreatic
Cancer Cells. Gastroentrology. Submitted . 2013
3.
Palmbos PL , Wu D, Dailey JM, Wilson TE. Recruitment of Saccharomyces cerevisiae Dnl4-Lif1 complex to a double-strand break requires interactions with
Yku80 and the Xrs2 FHA domain. Genetics. 2008 Dec;180(4):1809-19.
4.
Pitcher RS, Tonkin LM, Daley JM, Palmbos PL , Green AJ, Velting TL, Brzostek
A, Korycka-Machala M, Cresawn S, Dziadek J, Hatfull GF, Wilson TE, Doherty

AJ. Mycobacteriophage exploit NHEJ to facilitate genome circularization. Mol
Cell . 2006 Sept;23(5): 743-8.
5.
Palmbos PL , Daley JM, Wilson TE. Mutations of the Yku80 C-terminus and
Xrs2 FHA domain specifically block yeast nonhomologous end-joining. Mol Cell
Bio l. 2005 Dec;25(24):10782-90.
6.
Daley JM, Palmbos PL , Wu D, Wilson TE. Nonhomologous end joining in yeast. Annu Rev Genet . 2005;39:431-51.
7.
Della M, Palmbos PL *, Tseng HM, Tonkin LM, Daley JM, Topper LM, Pitcher
RS, Tomkinson AE, Wilson TE, Doherty AJ. Mycobacterial Ku and ligase proteins constitute a two-component NHEJ repair machine. Science . 2004 Oct
22;306(5696):683-5.
8.
Wilson TE, Topper LM, Palmbos PL . Nonhomologous end joining: bacteria join the chromosome breakdance. Trends Biochem Sci . 2003 Feb;28(2):62-6.
9.
Palmbos PL , Sytsma MJ, DeHeer DH, Bonnema JD. Macrophage exposure to particulate titanium induces phosphorylation of the protein tyrosine kinase lyn and the phospholipases Cgamma-1 and Cgamma-2. J Orthop Res . 20(3):483-9, 2002.
10.
Kalikin LM, Bugeaud EM, Palmbos PL , Lyons RH Jr, Petty EM. Genomic characterization of human SEC14L1 splice variants within a 17q25 candidate tumor suppressor gene region and identification of an unrelated embedded expressed sequence tag. Mamm Genome.
12(12):925-9 2001.
*Denotes co-first author status